4.7 Article

Enzymatic synthesis of low molecular weight heparins from N-sulfo heparosan depolymerized by heparanase or heparin lyase

期刊

CARBOHYDRATE POLYMERS
卷 295, 期 -, 页码 -

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.carbpol.2022.119825

关键词

Heparanase Bp; Heparinase III; Low molecular weight heparin; Enzymatic synthesis; Anticoagulant activity

资金

  1. GlycoMIP a National Science Founda- tion Materials Innovation Platform [DMR-1933525]
  2. Key Research and Development Program of Zhejiang [2021C03084]
  3. High -Level Talent Special Support Plan of Zhejiang Province [2019R52009]

向作者/读者索取更多资源

In this study, two LMWHs were enzymatically synthesized, and it was found that HepBp can be used to prepare a new type of LMWH with high anticoagulant activity.
Low-molecular-weight heparin (LMWH) is prepared from the controlled chemical or enzymatic depolymerization of animal sourced heparins. It has been widely used as an anticoagulant. Concerns about the shortcomings of animal-derived heparin and the contamination of supply chain demand biochemical approaches for synthesizing LMWH. In the present study, two LMWHs were enzymatically synthesized from low molecular weight N-sulfated heparosan (LMW-NSH) cleaved by recombinant hydrolase, endo-beta-glucuronidase, (HepBp) or heparin lyase III (HepIII), followed by subsequent sulfotransferase modifications. Structural characterization shows that LMWH chains prepared using HepBp had a saturated uronic acid residue at their reducing ends, while chains of LMWH prepared using HepIII had an unsaturated uronic acid residue at their non-reducing end. Both LMWHs had antifactor Xa and anti-factor IIa activities comparable to enoxaparin. This approach demonstrates that the hydrolase, HepBp, can be used to prepare a new type of LMWH that has no unsaturated uronic acid at its non-reducing end.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据